2024.03.19 (화)

  • 구름많음동두천 7.4℃
  • 구름조금강릉 10.5℃
  • 구름많음서울 7.9℃
  • 구름많음대전 7.7℃
  • 흐림대구 9.1℃
  • 흐림울산 11.2℃
  • 구름많음광주 10.6℃
  • 흐림부산 11.9℃
  • 맑음고창 11.4℃
  • 구름많음제주 13.8℃
  • 흐림강화 7.8℃
  • 흐림보은 6.3℃
  • 구름조금금산 8.5℃
  • 구름많음강진군 11.7℃
  • 구름많음경주시 11.6℃
  • 흐림거제 12.3℃
기상청 제공

경제

LFB SA Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors

[By NBC-1TV H. J Yook]LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors.

This Phase 3 clinical trial is a global open-label, multicenter study designed to evaluate the efficacy, safety and pharmacokinetics of LR769 in adolescent and adult hemophilia A and B patients with inhibitors. The study will evaluate two dosing regimens for the treatment of bleeding episodes and should be completed in 2015. More details can be found on www.clinicaltrials.gov, study identifier NCT02020369.

“The start of patient treatment is an important milestone in the development of LR769 for hemophilia A and B patients with inhibitors to Factor VIII or IX. LFB is committed to working with the hemophilia community to find new treatment options for this condition and to improve the lives of people with hemophilia,“ commented Christian Béchon, Chairman and Chief Executive Officer, LFB SA. ”Based on promising data from earlier studies, we believe that LR769 has the potential to be a significant advance for people with hemophilia, and we will fully explore its potential as the first new therapeutic option in more than 15 years."



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너